Treatment | Period (h) | pEC50 | Emaxa | n | |||
---|---|---|---|---|---|---|---|
Control | Treated | Control | Treated | Control | Treated | ||
BIX02188 (1 µM) | h 0–5 | 8.88 ± 0.04 | 8.87 ± 0.05 | 85.30 ± 1.68 | 86.32 ± 1.98 | 11 | 7 |
BIX02188 (10 μM) | 0–5 | 8.88 ± 0.04 | 8.08 ± 0.05*** | 85.30 ± 1.68 | 91.74 ± 2.93 | 11 | 6 |
BIX02188 (10 μM) | 4.75–5 | 8.81 ± 0.04 | 8.73 ± 0.08 | 86.90 ± 1.96 | 80.71 ± 2.80 | 7 | 6 |
SB203580 (1 µM) | 0–5 | 8.96 ± 0.05 | 8.76 ± 0.05 | 88.23 ± 2.00 | 83.52 ± 2.18 | 11 | 5 |
SB203580 (10 µM) | 0–5 | 8.96 ± 0.05 | 8.61 ± 0.07** | 88.23 ± 2.00 | 81.32 ± 2.73 | 11 | 7 |
SB203580 (10 µM) | 4.75–5 | 8.81 ± 0.04 | 8.76 ± 0.05 | 86.90 ± 1.96 | 80.58 ± 2.07 | 7 | 7 |
VX-702 (20 nM) | 0–5 | 9.00 ± 0.02 | 8.97 ± 0.08 | 77.47 ± 1.13 | 81.15 ± 2.69 | 11 | 5 |
VX-702 (200 nM) | 0–5 | 9.00 ± 0.02 | 8.47 ± 0.03*** | 77.47 ± 1.13 | 78.12 ± 1.54 | 11 | 7 |
VX-702 (200 nM) | 4.75–5 | 8.81 ± 0.04 | 8.79 ± 0.09 | 86.90 ± 1.96 | 87.96 ± 3.08 | 7 | 7 |
SP600125 (1 µM) | 0–5 | 8.87 ± 0.03 | 8.83 ± 0.03 | 89.74 ± 1.47 | 89.01 ± 1.57 | 9 | 7 |
SP600125 (3 µM) | 0–5 | 8.87 ± 0.03 | 8.28 ± 0.04*** | 89.74 ± 1.47 | 79.94 ± 1.91 | 9 | 7 |
SP600125 (3 µM) | 4.75–5 | 8.81 ± 0.04 | 8.61 ± 0.04 | 86.90 ± 1.96 | 77.23 ± 1.81 | 7 | 7 |
PD184353 (0.1 µM) | 0–5 | 8.85 ± 0.03 | 8.94 ± 0.06 | 80.12 ± 1.44 | 74.02 ± 2.13 | 13 | 7 |
PD184353 (1 µM) | 0–5 | 8.85 ± 0.03 | 8.75 ± 0.07 | 80.12 ± 1.44 | 75.89 ± 2.40 | 13 | 7 |